Ronald Bentsur
Directeur Général chez NUVECTIS PHARMA, INC.
Fortune : 21 M $ au 30/04/2024
Postes actifs de Ronald Bentsur
Sociétés | Poste | Début | Fin |
---|---|---|---|
NUVECTIS PHARMA, INC. | Directeur Général | 27/07/2020 | - |
Président | 27/07/2020 | - | |
Fondateur | 27/07/2020 | - | |
President | 27/07/2020 | - | |
BEYOND AIR, INC. | Directeur/Membre du Conseil | 01/08/2015 | - |
Independent Dir/Board Member | 01/08/2015 | - | |
Beyond Air Ltd.
Beyond Air Ltd. BiotechnologyHealth Technology Beyond Air, Ltd. is a clinical-stage medical device and biopharmaceutical company engaging in the development of nitric oxide generator and delivery system that uses nitric oxide generated from ambient air and delivers precise amounts of nitric oxide to the lungs for the potential treatment of respiratory and other diseases. The company was founded by Yossef Av-Gay, Amir Avniel, and David Greenberg in May 2011 and is headquartered in Rehovot, Israel. | Directeur/Membre du Conseil | 01/01/2017 | - |
Président | 01/08/2015 | 01/01/2017 | |
Ait Ltd.
Ait Ltd. BiotechnologyHealth Technology Ait Ltd. engages in research and development in biotechnology. The private company is located in Israel. The Israeli company was founded by Yossef Av-Gay, Amir Avniel, Avishai Abrahami. Amir Avniel has been the CEO of the company since 2011. | Président | 01/08/2015 | - |
Israel Biotech Fund
Israel Biotech Fund Investment ManagersFinance Israel Biotech Fund (Israel Biotech) is a venture capital firm founded in 2015 by Yuval Cabilly, David Sidransky, and Gidon Zairi. The firm is headquartered in Rehovot, Israel. | Consultant / Advisor | - | - |
Historique de carrière de Ronald Bentsur
Anciens postes connus de Ronald Bentsur
Sociétés | Poste | Début | Fin |
---|---|---|---|
STEMLINE THERAPEUTICS, INC. | Directeur/Membre du Conseil | 01/01/2009 | 01/06/2020 |
UROGEN PHARMA LTD. | Directeur/Membre du Conseil | 01/10/2015 | 03/01/2019 |
Directeur Général | 01/08/2015 | 03/01/2019 | |
KERYX BIOPHARMACEUTICALS | Directeur/Membre du Conseil | 16/06/2009 | 30/04/2015 |
Directeur Général | 20/05/2009 | 30/04/2015 | |
XTL BIOPHARMACEUTICALS LTD. | Directeur Général | 01/01/2006 | 01/04/2009 |
░░░░░ ░░░░░░░░░░░░░░░░░░ | ░░░░░░░░ ░░ ░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ | |
░░░░░ ░░░░░░░░ ░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░ ░░░░░░ ░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | - |
Formation de Ronald Bentsur
The Hebrew University of Jerusalem | Undergraduate Degree |
The Leonard N Stern School of Business | Masters Business Admin |
Statistiques
Internationale
Israël | 8 |
Etats-Unis | 6 |
2 |
Opérationnelle
Director/Board Member | 6 |
Chief Executive Officer | 4 |
Chairman | 3 |
Sectorielle
Health Technology | 9 |
Consumer Services | 3 |
Finance | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 4 |
---|---|
XTL BIOPHARMACEUTICALS LTD. | Health Technology |
UROGEN PHARMA LTD. | Health Technology |
NEXTGEN BIOMED LTD | Health Technology |
BEYOND AIR, INC. | Health Technology |
Entreprise privées | 7 |
---|---|
Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Keryx Biopharmaceuticals, Inc. engaged in the manufacture, development, and commercialization of medicines for use in treating human diseases. The company was founded in August 1, 2002 and was headquartered in Cambridge, MA. | Health Technology |
Stemline Therapeutics, Inc.
Stemline Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, acquisition, development, and commercialization of novel therapeutics for oncology indications of unmet medical need. Its clinical stage product candidates include SL-401, SL-801, and SL-701. The SL-401, is a targeted therapy directed to the interleukin-3 receptor (CD123) present on a malignancies. The SL-801, is a novel oral small molecule reversible inhibitor of XPO1, that has demonstrated in vivo and in vitro preclinical activity in solid and hematologic malignancies. The SL-701, is an immunotherapy designed to activate the immune system to attack tumors. The company was founded by Ivan Bergstein on August 8, 2003 and is headquartered in New York, NY. | Health Technology |
Beyond Air Ltd.
Beyond Air Ltd. BiotechnologyHealth Technology Beyond Air, Ltd. is a clinical-stage medical device and biopharmaceutical company engaging in the development of nitric oxide generator and delivery system that uses nitric oxide generated from ambient air and delivers precise amounts of nitric oxide to the lungs for the potential treatment of respiratory and other diseases. The company was founded by Yossef Av-Gay, Amir Avniel, and David Greenberg in May 2011 and is headquartered in Rehovot, Israel. | Health Technology |
Leumi Partners Underwriters Ltd. | |
Ait Ltd.
Ait Ltd. BiotechnologyHealth Technology Ait Ltd. engages in research and development in biotechnology. The private company is located in Israel. The Israeli company was founded by Yossef Av-Gay, Amir Avniel, Avishai Abrahami. Amir Avniel has been the CEO of the company since 2011. | Health Technology |
Nuvectis Pharma, Inc. | |
Israel Biotech Fund
Israel Biotech Fund Investment ManagersFinance Israel Biotech Fund (Israel Biotech) is a venture capital firm founded in 2015 by Yuval Cabilly, David Sidransky, and Gidon Zairi. The firm is headquartered in Rehovot, Israel. | Finance |
- Bourse
- Insiders
- Ronald Bentsur
- Expérience